Kaiser Washington Vaccine and Treatment Evaluation Unit â DMID 21-0004
$2,114,527UM1FY2022AINIH
Kaiser Foundation Research Institute, Oakland CA
Investigators
Linked publications, trials & patents
Paper 39774938Paper 38332733Paper 38105137Paper 37451878Paper 37433788Paper 36642379Paper 36001680Paper 35547849Paper 35139271Paper 35090580Paper 35081293Paper 34981072Paper 34907214Paper 34671773Paper 34599915Paper 34551225Paper 34549975Paper 34545372Paper 34519540Paper 34494017Paper 34385356Paper 34230930Paper 34103407Paper 34031659Paper 33882225Paper 33880474Paper 33822494Paper 33378609Paper 33270381Paper 32991794Paper 32663912Trial NCT05292391Trial NCT04785144Trial NCT04283461
Abstract
The 21-0004 protocol will evaluate the safety and immunogenicity of SARS-CoV-2 administered during pregnancy or postpartum. The Seattle Childrenâs Research Institute, a subcontractor to the Kaiser Washington VTEU, has been selected to perform SARS-CoV-2 pseudovirus neutralization assays for the 21-0004 trial. The NIH will provide funds for the assay work to the Kaiser Washington VTEU, which will then provide funds to the Seattle Childrenâs Research Institute via the existing subcontract. Kaiser Washington is not a clinical site for the 21-0004 trial and the work of the subcontractor is the only involvement of Kaiser Washington in that trial.
View original record on NIH RePORTER →